Two Herbs, One Question: Which Ayurvedic Cognitive Herb Fits the Need?

“Brain tonic” is too broad for a precise Ayurvedic choice. Poor retention, stress-related distractibility, disturbed sleep, mental fatigue, and progressive cognitive change are not interchangeable complaints. Brahmi and Shankhapushpi are both described as medhya in authoritative Ayurvedic sources, but their botanical identities, classical attributes, doses, and levels of modern clinical study differ substantially.

A second distinction is essential. The well-known passage in Charaka Samhita, Chikitsa Sthana 1/3/30–31, names Mandukaparni juice, Yashtimadhu powder with milk, Guduchi juice, and Shankhapushpi paste as especially intellect-promoting rasayanas. Bacopa monnieri is not one of the four drugs named in that passage. Nevertheless, the Ayurvedic Pharmacopoeia of India separately identifies Bacopa monnieri as Brahmi and assigns it the actions medhya and rasayana. Both herbs therefore have authentic Ayurvedic standing, but not through the same textual statement.

Brahmi (Bacopa monnieri): The Better-Studied Option for Memory

The Ayurvedic Pharmacopoeia of India defines Brahmi as the dried whole plant of Bacopa monnieri (Linn.) Wettst. Modern products may contain whole-plant powder or extracts standardized to selected saponins; these forms are not dose-equivalent and should not be treated as interchangeable.

Classical Ayurvedic Profile

Its recorded pharmacopoeial attributes are:

  • Rasa: madhura, tikta, kashaya — sweet, bitter, and astringent
  • Guna: laghu and sara — light and mobile or flowing
  • Virya: shita — cooling
  • Vipaka: madhura — sweet post-digestive effect
  • Karma: includes medhya, rasayana, matiprada, Vatahara, and Kaphahara

The pharmacopoeia lists Sarasvatarishta, Brahmi Ghrita, Brahmi Vati, Sarasvata Churna, and Smritisagara Rasa among important formulations associated with Brahmi. Raw herb, extract capsules, and compound formulations remain therapeutically distinct.

Human Clinical Evidence

Bacopa has a larger human evidence base than Convolvulus pluricaulis. A 2001 randomized, double-blind, placebo-controlled trial of a standardized extract reported improvements after 12 weeks in visual information-processing speed, learning rate, memory consolidation, and state anxiety. A separate 2002 trial in adults aged 40–65 found a significant effect on retention of newly learned word pairs, with the pattern suggesting reduced forgetting rather than a broad improvement across every memory measure.

A 2012 systematic review found the most consistent signal in memory free recall, while effects in other cognitive domains were less consistent. A 2014 meta-analysis of randomized controlled trials concluded that Bacopa had potential cognitive benefits, particularly for speed of attention, while also calling for larger and better-designed trials. Standardized Bacopa extracts may improve selected outcomes in some adults after repeated use, but they are not established dementia treatments or universal remedies for poor concentration.

More recent evidence also argues against certainty. A 12-week randomized trial published in 2025 found no greater improvement in cognitive performance than placebo, although it reported signals for reduced stress and fatigue. Differences among extracts and study designs make product-specific interpretation important.

What Is Known About Mechanism

Bacopa contains dammarane-type triterpenoid saponins commonly grouped under the term bacosides. Laboratory and animal studies have examined antioxidant activity, cholinergic signaling, monoamine systems, synaptic plasticity, and neuroprotective pathways. Some human studies have also measured acetylcholinesterase-related outcomes. These findings do not justify equating Bacopa with donepezil or reducing its effects to one neurotransmitter pathway.

Shankhapushpi (Convolvulus pluricaulis): Classical Medhya Rasayana with Limited Human Data

The Ayurvedic Pharmacopoeia of India defines Shankhapushpi as the whole plant of Convolvulus pluricaulis Choisy. It also notes that Clitoria ternatea and Evolvulus alsinoides are used as Shankhapushpi in some parts of India. A label carrying the common name “Shankhpushpi” may therefore contain a different species from the one used in a study or monograph.

Classical Ayurvedic Profile

For pharmacopoeial Convolvulus pluricaulis, the recorded Ayurvedic attributes are:

  • Rasa: tikta, kashaya — bitter and astringent
  • Guna: sara — mobile or flowing
  • Virya: shita — cooling
  • Vipaka: madhura — sweet post-digestive effect
  • Karma: includes medhya, rasayana, balya, ayushya, Kaphahara, Pittahara, and mohanashaka

Charaka’s medhya-rasayana passage specifies Shankhapushpi in paste form. The pharmacopoeia lists Brahmi Ghrita, Agastyaharitaki Rasayana, Brahma Rasayana, Manasamitra Vataka, Gorocanadi Vati, and Brahmi Vati among important formulations associated with Shankhapushpi. A formulation name containing “Brahmi” does not establish that every modern product contains both herbs.

Experimental Evidence and Its Limits

Animal studies have reported memory-related, anxiolytic, and central nervous system depressant effects from Convolvulus pluricaulis extracts. A 2011 study evaluated several extracts in rodents and found activity in learning, memory, anxiety, and locomotor models, with results varying by extract and dose. Phytochemical investigations describe alkaloids, coumarins, flavonoids, and sterols, with profiles varying by material and extraction method.

Human clinical evidence for authenticated Convolvulus pluricaulis remains sparse. It is therefore inaccurate to assign it a proven four-to-six-week onset, a validated GABA mechanism in patients, or superiority over Bacopa for anxiety. Its contemporary use is best framed as a classical Ayurvedic choice requiring individualized prescribing, not a standardized nootropic protocol.

Head-to-Head Comparison

No robust direct human trial establishes that one of these herbs is categorically superior to the other. A useful comparison separates classical pharmacopoeial information from modern clinical evidence.

Parameter Brahmi (Bacopa monnieri) Shankhapushpi (Convolvulus pluricaulis)
Official drug part Dried whole plant Whole plant
Classical standing Medhya and rasayana in the API monograph One of Charaka’s four specified medhya rasayanas; also medhya and rasayana in the API
Rasa Madhura, tikta, kashaya Tikta, kashaya
Guna Laghu, sara Sara
Virya Shita Shita
Vipaka Madhura Madhura
Dosha-related API karma Vatahara and Kaphahara are listed Kaphahara and Pittahara are listed
API powder dose 1–3 g 3–8 g
Modern evidence Several small human trials and systematic reviews; outcomes are mixed Mainly animal and laboratory studies; limited authenticated human data
Common practical issue Extract strengths and bacoside specifications differ Several botanical species may be sold under the same common name

Clinical Decision Framework

Ayurvedic selection should consider the person, the complaint, digestive tolerance, concurrent medicines, and the exact preparation. Constitution alone is insufficient, and neither herb should be chosen solely from an online dosha quiz.

When Brahmi May Be the More Defensible Starting Point

Brahmi is the more evidence-supported option when the goal is a time-limited trial for memory retention or selected attention outcomes in an otherwise medically assessed adult. Considerations include:

  • Difficulty retaining newly learned information without sudden or progressive neurological symptoms
  • A preference for a product standardized in the same way as a published human trial
  • Willingness to use it consistently for the trial period rather than expecting an immediate stimulant effect
  • Access to professional review of gastrointestinal tolerance, thyroid status, and possible medicine interactions

When Shankhapushpi May Be Considered

Shankhapushpi may be selected within an Ayurvedic plan when its classical medhya, rasayana, Pittahara, and Kaphahara profile fits the assessed presentation. Practical requirements are:

  • Confirmation that the product contains Convolvulus pluricaulis rather than an unspecified substitute
  • Use of the whole herb or a clearly characterized preparation rather than assuming all syrups are equivalent
  • Practitioner supervision when the complaint includes anxiety, insomnia, seizures, thyroid disease, or regular medication use
  • Realistic expectations, because a clinically validated onset time and comparative superiority have not been established

Should They Be Combined?

A combination is not automatically more effective. Classical and proprietary formulations may contain multiple medhya herbs, but their rationale, proportions, processing, and adjuvants are formulation-specific. A fixed schedule of 300 mg Bacopa extract plus 3 g Shankhapushpi is neither a universal classical protocol nor a validated combined regimen. Combination use should follow a qualified practitioner’s assessment.

Dosing and Dosage Forms

Dose must be tied to the exact material. A gram dose of whole-plant powder cannot be converted directly into a milligram dose of concentrated extract, and commercial syrups may also contain several ingredients.

Brahmi

The Ayurvedic Pharmacopoeia of India gives 1–3 g of the drug in powder form. Several adult cognition trials used about 300 mg daily of a particular standardized extract, but the extract specification is part of the dose and cannot be omitted. Brahmi Ghrita is an official classical formulation associated with the herb; its dose should follow the applicable formulary, product directions, and practitioner advice rather than being inferred from raw-herb dosing.

Shankhapushpi

The pharmacopoeial dose is 3–8 g of the drug in powder form. It does not establish a universal dose for juice, syrup, tablets, or concentrated extracts. Because several species circulate under the common name, check the botanical name and plant part.

Ghee, Milk, and Black Pepper

Ghee has an established place in Ayurvedic dietetics and in classical medicated-ghee formulations used for medhya purposes. That use does not prove that ghee increases absorption of every constituent in either herb. Likewise, adding black pepper is not automatically appropriate; piperine can alter drug metabolism, and no universal Brahmi–Shankhapushpi protocol requires it.

Safety Considerations and Interactions

“Natural” does not mean interaction-free. Product authentication, dose, duration, age, pregnancy status, medical conditions, and concurrent medicines all affect safety.

  • Brahmi: Human trials most often report gastrointestinal effects such as increased stool frequency, abdominal cramps, and nausea. Caution is appropriate with thyroid disease or thyroid hormone, cholinergic or anticholinergic medicines, and drugs affected by CYP enzymes.
  • Shankhapushpi: Human safety and interaction data for authenticated Convolvulus pluricaulis are limited. Do not use animal thyroid findings to alter levothyroxine, antithyroid medicine, or endocrine care.
  • Pregnancy and breastfeeding: Avoid self-prescribing either herb because adequate human safety data and product consistency are lacking.
  • Children and older adults: Dosing should be individualized by a qualified Ayurvedic practitioner or healthcare professional, especially when other medicines are used.
  • Persistent symptoms: New, worsening, or progressive memory change, confusion, severe anxiety, sleep disruption, or functional decline requires medical evaluation rather than treatment with a nootropic supplement alone.

Consult a qualified Ayurvedic practitioner and the relevant healthcare provider before starting either herb, particularly if you are pregnant, breastfeeding, treating a thyroid or neurological condition, or taking prescription medication.

Bottom Line

Brahmi and Shankhapushpi are not interchangeable “brain herbs.” Bacopa monnieri has the stronger human research base for selected memory and attention outcomes, although results are mixed and extract-specific. Convolvulus pluricaulis has a particularly clear classical position as one of Charaka’s medhya rasayanas, but its modern human evidence is much thinner and botanical substitution is a major practical concern. The sound choice depends on authenticated material, the precise clinical goal, the Ayurvedic assessment, and safety review—not on claims of a universal best nootropic.

References

  1. Ayurvedic Pharmacopoeia of India
  2. Ayurvedic Pharmacopoeia of India
  3. Charaka Samhita — Buddhi
  4. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects (2001), PubMed
  5. Chronic effects of Brahmi (Bacopa monnieri) on human memory (2002), PubMed
  6. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials (2012), PubMed
  7. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract (2014), PubMed
  8. The Effects of a Bacopa monnieri Extract (Bacumen(®)) on Cognition, Stress, and Fatigue in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Trial (2025), PubMed
  9. Neuropharmacological review of the nootropic herb Bacopa monnieri (2013), PubMed Central
  10. Effects of 12-Week Bacopa monnieri Consumption on Attention, Cognitive Processing, Working Memory, and Functions of Both Cholinergic and Monoaminergic Systems in Healthy Elderly Volunteers (2012), PubMed
  11. Nootropic, anxiolytic and CNS-depressant studies on different plant sources of shankhpushpi (2011), PubMed
  12. Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus – A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies (2020), PubMed Central
  13. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial (2010), PubMed
  14. NCBI
  15. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4 (2002), PubMed
  16. Predicting Food-Drug Interactions between Piperine and CYP3A4 Substrate Drugs Using PBPK Modeling (2024), PubMed